Top Page
Helius Medical Technologies
(NASDAQ:HSDT)
Helius Medical Technologies (HSDT) vs. SPDR S&P 500 ETF (SPY)
Helius Medical Technologies Business Overview & Revenue Model
Helius Medical Technologies Earnings Call Summary
Helius Medical Technologies Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 520.00K | 644.00K | 787.00K | 522.00K | 661.00K |
| Gross Profit | -62.00K | 61.00K | 324.00K | 224.00K | -90.00K |
| EBITDA | -13.80M | -12.11M | -14.50M | -17.82M | -13.65M |
| Net Income | -11.74M | -8.85M | -14.07M | -18.13M | -14.13M |
Balance Sheet | |||||
| Total Assets | 3.54M | 7.69M | 17.29M | 14.10M | 6.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 5.18M | 14.55M | 11.01M | 3.33M |
| Total Debt | 12.00K | 57.00K | 110.00K | 3.00K | 91.00K |
| Total Liabilities | 2.48M | 5.34M | 9.14M | 2.85M | 2.68M |
| Stockholders Equity | 1.06M | 2.35M | 8.15M | 11.26M | 3.87M |
Cash Flow | |||||
| Free Cash Flow | -11.05M | -10.45M | -14.33M | -13.44M | -11.80M |
| Operating Cash Flow | -11.04M | -10.42M | -14.31M | -13.39M | -11.74M |
| Investing Cash Flow | -5.00K | -29.00K | -11.00K | -56.00K | -9.00K |
| Financing Cash Flow | 6.95M | 1.08M | 17.87M | 21.13M | 9.64M |
Helius Medical Technologies Technical Analysis
Helius Medical Technologies Risk Analysis
Helius Medical Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $34.28M | ― | -450.47% | ― | 9.47% | 81.37% | |
54 Neutral | $10.43M | 0.85 | -499.57% | ― | -33.92% | ― | |
52 Neutral | $7.36B | -0.07 | -63.77% | 2.81% | 16.35% | 0.03% | |
43 Neutral | $3.90M | ― | -218.77% | ― | -33.67% | 91.72% | |
42 Neutral | $6.95M | ― | -155.20% | ― | 9.90% | 94.56% | |
39 Underperform | $6.02M | ― | -800.00% | ― | -35.03% | 57.39% |
Helius Medical Technologies Corporate Events
On July 21, 2025, Helius Medical Technologies announced the successful results of their PoNS Stroke Registrational Program, which began in March 2024. The program’s clinical trials demonstrated significant improvements in gait and balance deficits in stroke patients, with minimal adverse events, supporting an upcoming FDA submission for a new indication under the Breakthrough Device Designation. The trials involved 159 patients and were conducted across 10 clinical sites in the US and Canada, highlighting the potential impact on stroke rehabilitation and the company’s market positioning.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
On July 7, 2025, Helius Medical Technologies announced that it has regained compliance with Nasdaq’s equity and minimum bid price requirements, ensuring its continued listing on The Nasdaq Capital Market. The company will be under a mandatory monitoring period until July 7, 2026, during which any further non-compliance could lead to a delisting determination without the opportunity for a compliance plan or additional time.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
On July 7, 2025, Helius Medical Technologies filed an updated Prospectus Supplement to offer and sell up to $25 million of its common stock through Roth Capital Partners. The proceeds from this offering are intended for working capital and general corporate purposes, including commercialization efforts and research and development activities.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
On June 20, 2025, Helius Medical Technologies‘ Board of Directors approved a 1-for-50 reverse stock split of its Class A common stock, effective July 1, 2025, to meet Nasdaq’s listing requirements. This move will reduce the number of outstanding shares from approximately 33.8 million to 0.7 million, while the stock will continue trading under the symbol ‘HSDT’ on a split-adjusted basis starting July 1, 2025.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Helius Medical Technologies, Inc. faced a compliance issue with Nasdaq’s minimum stockholders’ equity requirement after their equity fell below $2.5 million as of December 31, 2024. On June 6, 2025, the company completed a public offering raising approximately $8.1 million, which helped them meet the equity requirement. As of June 17, 2025, Helius Medical Technologies believes it has regained compliance and awaits Nasdaq’s confirmation for continued listing.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Helius Medical Technologies announced that its Board of Directors approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares of common stock by 20% of the Fully Diluted Shares. This amendment was approved by stockholders on May 23, 2025, and resulted in an increase to 7.1 million shares available under the plan as of June 16, 2025, following a public offering.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
On June 3, 2025, Helius Medical Technologies received formal notification from Nasdaq confirming its compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Despite this compliance, the company must still meet the equity requirement by June 30, 2025, to fulfill all Nasdaq listing criteria, keeping the Nasdaq Listing Qualifications hearing process open until then.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
At a special meeting on May 23, 2025, Helius Medical Technologies‘ stockholders approved several significant proposals, including a reverse stock split and an increase in authorized shares to 800 million. These decisions aim to ensure compliance with Nasdaq listing requirements and facilitate potential financing, impacting the company’s operational and strategic positioning.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.